People with early-stage Parkinson’s disease and non-motor symptoms such as depression, anxiety, urinary tract issues, and hallucinations or delusions are more likely to experience sleep disorders, a recent study has found. Better cognitive function appears to predict better sleep quality in these patients, according to the…
Depression and anxiety can be prevalent among elderly people hospitalized with Parkinson’s disease, and is associated with malnourishment or poor nutrition, a study from Germany suggests. Findings also indicate that malnutrition is more prominent among men with Parkinson’s whose disease is more advanced or of a longer duration. The study,…
A clinical trial that’s multi-arm and multi-stage (MAMS) could quicken development of promising therapies for Parkinson’s disease (PD) by allowing multiple treatments to be tested simultaneously. MAMS trials, most commonly used across cancers, may be a way of advancing work toward a first therapy that can delay or stop Parkinson’s…
Vanderbilt University announced the opening of the Warren Center for Neuroscience Drug Discovery, promoting research into treatments for neurological disorders such as Parkinson’s disease, Alzheimer’s, and schizophrenia. The center, which will specialize in translating basic research into viable treatments, was made possible by a $20 million donation from…
Alcohol consumption does not seem to increase the risk of Parkinson’s disease, according to data from a large European study. The study, “Alcohol Consumption and Risk of Parkinson’s Disease: Data from a Large Prospective European Cohort,” was published in the journal Movement Disorders. Although the…
People who drink more caffeinated beverages and have high blood levels of urate appear to have a significantly lower chance of developing Parkinson’s disease, a study has found. While the research provides further support that caffeine and urate are protective factors against Parkinson’s, scientists caution that the therapeutic potential…
GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that…
The protein RasGRP1 is a key culprit for involuntary movements that arise from dopamine replacement therapies used to treat Parkinson’s disease, a new study done in animals suggests. Targeting this protein may be a therapeutic strategy to prevent these motor problems, while still receiving the benefits of treatment. The…
Certain features of metabolic syndrome may be more prevalent in people with Parkinson’s disease-associated mutations in the gene LRRK2, new research suggests. The research abstract “Metabolic syndrome and genetic Parkinson’s disease, the case of LRRK2 and GBA” was published online. It was to be presented at the 2020 annual meeting…
To help patients and their families cope with the global COVID-19 outbreak, The Michael J. Fox Foundation (MJFF) is launching a limited-series podcast. The series begins today, May 6, and is part of MJFF’s ongoing Parkinson’s Podcast. It’s available every other Wednesday on michaeljfox.org/podcasts, Google…
Get regular updates to your inbox.
